INTRODUCTION
Acute lower urinary tract infections (UTIs) in adults consist of episodes of acute cystitis. They occur in otherwise healthy individuals, mostly women, with no risk factors such as underlying disease or urinary tract abnormalities [1] . It is estimated that 1 in 2 women will have at least 1 episode of UTI in their lifetime, and UTIs are at least 50 times more common in premenopausal women than in men [2] . Furthermore, up to 20% of women with acute cystitis develop recurrent uncomplicated UTIs (3 or more episodes per year) [1] . Patients experience a psychological burden because they live with the anxiety of sudden acute episodes. In the United States, UTIs are responsible for seven million medical visits a year, including two million for cystitis alone, with three million patients treated with antibiotics. The total estimated cost is $3.5 billion; in Europe, the estimated cost is €1.5 billion [3, 4] .
The standard symptoms of acute uncomplicated UTIs (cystitis) include acute dysuria, pollakiuria, pain and burning associated with micturition, urgent need to urinate, as well as suprapubic tenderness without fever. Escherichia coli strains are the most common uropathogens, found in 80% of urine specimens from patients with lower acute uncomplicated UTI (cystitis), followed by Staphylococcus saprophyticus (5-15%), and aerobic Gram-negative bacteria, such as Klebsiella pneumoniae and Proteus mirabilis (5-10%) [5] . Although pathogen identification is essential for testing antimicrobial susceptibility and selecting appropriate therapy, it is not routinely performed. In the European Association of Urology (EAU)
guidelines [1] , pathogen identification is recommended only in cases of pregnancy, recurring UTI, or fever and flank pain (to exclude acute pyelonephritis) [6] . Empirical courses of antibiotics are generally effective in treating cystitis (single dosing or courses of 3-7 days), and the recommended antibiotics include fosfomycin, nitrofurantoin, cephalosporins, and trimethoprimsulfamethoxazole (TMP-SMX) [7] . However, bacterial re-colonization can lead to relapses or re-infections due to bacterial reservoirs [8] or drug resistance [9] 
Assessment Scales
QoL is an outcome that can only be assessed by the subjects themselves, without reference to any norm. This is a specific approach in which the patients express their perception of the situation and the satisfaction (or dissatisfaction) they experience compared with their expectations [28] . Therefore, QoL assessment was made using two specific questionnaires: a generic form on anxiety and depression disorders (i.e., the HAD scale) [26] and a UTIspecific questionnaire on the functional and social handicaps associated with UTIs (i.e., the Leicester impact scale) [27] .
Assessment of Emotional Problems
Emotional problems experienced by patients during the previous week were assessed using the HAD scale, which provides a reliable method of detecting the most common signs of anxiety and depressive disorders [26] . The questionnaire comprises 14 questions (7 evaluate anxiety and 7 evaluate depression).
Each reply has a value of 0-3, and the assessment was made in a semi-quantitative manner using an adverb or qualifying short sentence to evaluate symptom intensity. Therefore, the possible total score ranged from 0 to 42, with both anxiety and depression subscales ranging from 0 to 21.
The HAD scores were divided into three ranges to assess the presence of anxiety or 
Assessment of Social or Functional Handicap
Social or functional handicap was assessed using the Leicester impact scale. This is a valid and reliable, interviewer-administered QoL tool for patients with urinary storage symptoms [27] . It was used to determine the impact of urinary problems on daily activities (part 1) and on mood and behavior (part 2 
RESULTS

Patient Disposition
A total of 699 patients from seven countries were initially enrolled in the study. included in the primary endpoint analysis ('analysis population'). All patients who received OM-89 prophylaxis at the standard posology of 90 consecutive days (about 3 months) were followed up for a period of 3 months after treatment discontinuation.
Baseline and Day 180 Results
The most frequently reported urinary symptoms concerning the last infection were recorded at Day 0 (baseline). These were: pain and/or burning during micturition (93.7%), pollakiuria (82.4%), and dysuria (80.1%).
Approximately, one-third (29.8%) of patients reported asthenia. On Day 180, the population of patients suffering from asthenia or dysuria was reduced by approximately half, and there was a reduction of over 30% in the number of patients suffering from pollakiuria or pain/ burning during micturition (Fig. 1) .
The Wilcoxon test (P B 0.0001) showed that the mean number of urinary infections was 2.7
[standard deviation (SD) = 1.2] during the 6 months prior to study entry, measured on Day 0, and 1.1 (SD = 1.1) during the 6-month study period, measured on Day 180; this represents a statistically significant decrease of 1.6 (SD = 1.6).
During the study, 5% of patients did not receive any preventative treatment for UTI. Of the remaining 95%, the vast majority (94.4%) were given OM-89 (1 capsule a day for 90 days), followed by a 3-month treatment-free period.
Among the analysis population, 53.7% of patients were treated for acute UTI episodes:
41.6% of them received antibiotics, while the remaining 12.1% received unspecified other treatments.
At baseline, the HAD score revealed that 177 (32%), 153 (27.7%), and 12 (2.2%) patients exhibited mild, moderate, and severe levels of depression, respectively. The mean HAD anxiety subscale score was 10.3 (SD = 4.1, range 0-21), and the mean HAD depression subscale score was 6.4 (SD = 3.6, range 0-18). In total, 342 patients (61.8%) had at least minor emotional disorders, 165 (29.9%) of whom presented with a high anxious-depressive state.
At Day 180, the proportion of patients with possibly clinically relevant anxiety/depression levels (mild to severe anxiety or depression) decreased. The difference was more significant for the anxiety score, with a total reduction of 38.5% from Day 0 to Day 180 ( Table 1 ). The total HAD score at Day 180 indicated a 30.9% increase in patients with a normal score (below 14) , and a total decrease of 31% in patients experiencing mild to severe anxiety or depression (total HAD scores between 15 and 42; Fig. 2) . At Day 180, the mean HAD anxiety subscale score was 6.6 (SD = 3.7), the mean HAD depression score was 4.8 (SD = 3.5), and the total HAD score was 11.4 (SD = 6.5), representing a statistically significant decrease in total HAD score of 32.1% from baseline (P B 0.0001). The mean number of urinary episodes was 2.7 (SD = 1.2) on Day 0, and 1.1 (SD = 1.1) on Day 180, showing a statistically significant decrease of 59.3% from baseline (P B 0.0001). Thus, there was a correlation trend between the reduction in the numbers of UTIs from Day 0 to Day 180 and the reduction in the anxiety, depression, and total HAD scores, suggesting a lessening of emotional problems with decreasing UTI incidence (Fig. 3) . There was a correlation trend between the reduction in number of UTIs from Day 0 to 
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Percentage (%) Fig. 2 Total HAD score at Day 0 and Day 180-analysis population (N = 575, some data is missing). The HAD questionnaire comprises 14 questions (7 evaluate anxiety and 7 evaluate depression). Each reply has a value of 0-3, giving a possible total score ranging from 0 to 42. Higher scores indicate higher levels of anxiety and depression.
HAD hospital anxiety and depression
Day 180 and the reduction in the activity, feeling, and total Leicester scores. These statistically significant reductions suggest a lessening of social and functional handicap with decreasing UTI incidence (Fig. 4) .
Physicians reported overall improvement as 'much better' or 'very much better' in the vast majority (82.4%) of patients. Furthermore, 12.7% of patients reported a 'slightly better' feeling, and only 3.9% reported 'unchanged' feeling. The remaining 1% of patients did not report on their improvement. between the mean Leicester score and the mean number of UTIs, reinforcing the previously described study outcomes.
Most physicians selected immunoactive E. coli extract to prevent cystitis (94.4% of the study population were treated with immunoactive non-antimicrobial prophylaxis, OM-89), rather than prophylaxis with antibiotics. Interestingly, this choice of prophylaxis anticipated future EAU guidelines [1] . The immunoactive E. coli extract was first mentioned in the 2008 EAU guidelines, and was later recommended in the 2010 update [1] . In the same update, a long-term, doubleblind, placebo-controlled study [13] was referred to, which evaluated 453 patients who received either immunotherapeutic E. coli (OM-89) or matching placebo. The results showed a highly significant reduction (34%, P = 0.001) in UTI recurrences in the active treatment group compared with placebo. The current EAU guidelines [7] recommend using antimicrobial prophylaxis only when non-antimicrobial alternatives have failed. Among the available strategies, OM-89 is the most studied and has the highest level (1a) of clinical evidence, with a Grade B recommendation. [18, 25] . A clear improvement in QoL provided by effective prophylaxis, such as OM-89, has been revealed by this investigation.
In conclusion, this study highlights the need for further randomized double-blind controlled trials to confirm that non-antimicrobial prophylaxis (OM-89) improves rUTI management and patient QoL.
CONCLUSION
Our results showed that rUTI had a negative impact on patients' QoL and that effective alternative prophylaxis significantly improved their QoL.
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